Back to overview

Neumirna Receives 2024 CURE Epilepsy Catalyst Award

$250,000 in funding to support biomarker research and development of RNA therapy for drug-resistant epilepsy

We are honored to announce that Neumirna Therapeutics has received the 2024 CURE Epilepsy Catalyst Award. This generous funding ($250,000 over two years) will help us advance critical biomarker research needed to develop and deliver our lead candidate NMT.001 to patients with drug-resistant epilepsy.

"CURE and Neumirna Therapeutics are united by a shared mission: to drive forward disease-modifying therapies with the potential to cure epilepsy," said our founder and PI on the project, Dr. Henrik Klitgaard. "Biomarkers are essential because they ensure we match the right drug to the right patient. Thanks to CURE’s support, we can pursue both drug and biomarker discovery – bringing us closer to transforming how epilepsy is treated."

CURE Epilepsy is the leading nonprofit epilepsy research organization solely dedicated to funding groundbreaking research with the goal of finding a cure. The Catalyst Award is given to cutting-edge, novel research projects that seek to accelerate treatments, develop tools to improve outcomes, and get us to cures so that we can live in a world free of seizures.

We are grateful to CURE Epilepsy and their sponsors for believing in our vision and our ability to turn funding into tangible benefits for patients.

Funding
Awards
12.6.2025
Neumirna Receives 2024 CURE Epilepsy Catalyst Award
$250,000 in funding to support biomarker research and development of RNA therapy for drug-resistant epilepsy
Read full article
Awards
Funding
11.6.2025
Neumirna Receives 2025 Epilepsy Foundation Shark Tank Investment
$200,000 award supports Neumirna’s RNA-based approach to innovation in epilepsy treatment
Read full article
Awards
27.3.2025
Neumirna Wins Nordic Star Award at NLS Days 2023
Neumirna has been awarded the Nordic Star Award at NLS Days 2023, recognizing the company as the start-up with the highest investment potential.
Read full article